Last reviewed · How we verify
GS-5745
At a glance
| Generic name | GS-5745 |
|---|---|
| Sponsor | Gilead Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Diarrhoea
- Fatigue
- Vomiting
- Decreased appetite
- Asthenia
- Constipation
- Anaemia
- Neutropenia
- Peripheral sensory neuropathy
- Abdominal pain
- Thrombocytopenia
Key clinical trials
- A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) (PHASE2, PHASE3)
- A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton. (PHASE1, PHASE2)
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis (PHASE1)
- Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE1)
- Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE2)
- Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD) (PHASE1)
- Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (PHASE1)
- Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GS-5745 CI brief — competitive landscape report
- GS-5745 updates RSS · CI watch RSS
- Gilead Sciences portfolio CI